from mild hypercalcaemia of undetermined cause, bone metabolism as measured by serum parameters is essentially normal in most rheumatoid patients. 3 We have failed to show any abnormality of serum levels of 25-hydroxyvitamin D34 or of la,25-dihydroxyvitamin D35 in patients with rheumatoid arthritis, though an increased bone metabolisr.m has recently been demonstrated in this disease.6 There is undoubtedly a juxta-articular osteopenia in rheumatoid arthritis, most marked around the most inflamed joints. Since anabolic steroids are frequently used in the management of osteoporosis7 and since a beneficial effect of their use in this condition can be measured by neutron activation analysis,8 9 it seemed appropriate to evaluate nandrolone decanoate as a typical anabolic steroid using this technique in rheumatoid arthritis. We also added single photon absorptiometry as a localised 237 assessment of bone density at the distal femur. "' This method was felt to supersede earlier assessments of osteopenia in rheumatoid arthritis that used cortical thickness.
Patients and methods
Forty seven postmenopausal female patients were recruited for the study. All patients had classical or definite rheumatoid arthritis according to the American Rheumatism Association criteria, 12 and the arthritis was of at least one year's duration. Patients had to be physically able to complete the somewhat arduous neutron activation analysis assessments. Exclusion criteria were: (a) patients who had received any anabolic steroids within the previous two years; (b) patients with a known sensitivity to nandrolone decanoate; (c) patients taking vitamin D or analogues; (d) patients with abnormal thyroid or parathyroid function; (e) patients receiving oestrogen therapy; and (f) patients who had received cytotoxic therapy within the previous year.
Patients were allocated at random to one of two groups. Those in the first group received all existing antirheumatoid arthritis therapy in constant dosage with the addition of nandrolone decanoate, 50 mg given by intramuscular injection every three weeks for a period of two years. The second (controlled) group received all existing antirheumatoid arthritis therapy in constant dosage but had no injections of nandrolone decanoate. In view of the objective nature of the assessments, and at the insistence of the Medical Ethics Committee, placebo injections or tablets were not given. The study was thus a single blind parallel group study.
On admission to the study demographic data were recorded, including date of birth, weight, height, occupation, gynaecological history, and details of the extent of the arthritis. Recent '4 The standard deviation of the bone index was 0-43 g/cm, representing 5-8% of the subjects' measured values; bone index/bone width had a standard deviation of 0-08 g/cm2, i.e., 3-4% of the subjects' measured values.
The power of the study to ascertain whether or not total body calcium, bone index, and bone index/bone width changed more in one group than the other was assessed, assuming initially that measurements made only at the beginning and end of the study would be analysed. The following additional assumptions were made: (a) the measurements made in this study would have the same reproducibilities as those described above; (b) the standard deviation of each measured change in each group would be determined by the reproducibility of the method rather than by variability in the actual changes suffered by individual patients; and (c) the measured changes in each group would be normally distributed.
The calculation showed that with 24 patients in each group there would be a 90% chance of detecting, at the 5% level of significance, a difference between the mean changes of total body calcium in the two groups of 34 g. Thus the study was very likely to detect a difference of 37 g, as found in a similar study of a different anabolic steroid.8 The corresponding limits of detection for bone index and bone index/bone width were 0-4 g/cm and 0-08 g/cm2 respectively. We knew of no comparable study that would indicate the likely differences between the groups for these quantities. Thirteen patients failed to complete the two year study, five from the control group and eight from the treatment group. In the control group one patient died, two declined to continue with neutron activation analysis, and two withdrew for personal reasons. In the nandrolone tNSAIDs=non-steroidal anti-inflammatory drugs.
group Table 2 . At the first assessment, before the start of treatment, the patient groups were significantly different with respect to their articular index scores. Other clinical variables suggested that the control patients tended to be more severely affected by arthritis, though allocation had been by random code, and none of the other differences were statistically significant. Over the course of the study grip strength measurements showed a slight improvement in both treatment groups, but other variables suggested a slight deterioration in the patients' condition over the two year period. In no case was there a significant difference between the treatment groups when comparing the changes over 24 months.
Laboratory data are shown in Table 3 . Significant haematological changes were a rise in haemoglobin and packed cell volume on treatment (both p<001). There was no significant change in serum calcium but a significant fall in serum phosphate on treatment (p<0-01). There was no change in urinary calcium/creatinine or phosphate/creatinine ratios but a significant fall in hydroxyproline/creatinine ratio with treatment (p<005). No significant changes occurred with treatment for bone index/ bone width or for total body calcium or phosphorus or body weight, but both total body potassium (p<001) and nitrogen (p<0-01) increased with treatment.
When x rays were read blind no improvement in bone density of the spine was seen with treatment. Rheumatoid deterioration of the hands and feet continued equally in both groups. Side effects were more frequently seen in the treatment group. The principal effects were hoarseness, slight facial hair growth, and occasionally breast enlargement.
Discussion
The imbalance of baseline clinical assessments between the two groups occurred despite the strict allocation by a random code and probably reflects the relatively small number of patients recruited to the study. Nevertheless, a study of this magnitude stretched the full resources of the large rheumatology clinic over a two year period and it was not urinary hydroxyproline/creatinine ratio in the treatment group, perhaps reflecting a decrease in collagen breakdown, though this could also reflect an increase in urinary creatinine in the treatment group.
We found no evidence to suggest that treatment with nandrolone decanoate affected bone metabolism in postmenopausal rheumatoid patients. It should be stressed, however, that total body calcium and bone index measurement did not show any loss of bone in control patients over the two year course of this study. In spite of our careful selection criteria it remains a possibility that the rheumatoid patients under study were not susceptible to osteoporosis. Alternatively, it may be that mineral was lost predominantly from trabecular bone. Both neutron activation and photon absorptiometry measure trabecular and cortical bone together, and neither may be sufficiently sensitive to changes that affect only trabecular bone. Because the skeletal changes recorded are much smaller than those required to attain significance, the chances of a type II error arising in this study are remote. In future studies it may be preferable to measure the mineral content of vertebrae, which consist predominantly of trabecular bone, by dual photon absorptiometry, or to measure the trabecular component of long bones by quantitative computed tomography. '8 Previous studies using single photon absorptiometry had shown that bone mass was lower than normal in patients with arthritic changes.19 The opinion was expressed that reduced physical activity rather than the arthritis was the cause of low bone mass. Despite improved wellbeing and significant improvement in total body nitrogen and haemoglobin levels there was no significant improvement in bone mass in the present series, nor was there any significant difference in physical activity between the two groups. In view of the previous findings this would suggest that increased total body nitrogen and haemoglobin levels per se do not lead to any real improvement in the condition. This suggests that other factors, perhaps of a psychological nature, might be more important in achieving better physical activity levels in patients with arthritis.
Our results contrast with those of Reid et al, who also used neutron activation analysis in patients with rheumatoid arthritis treated with and without steroids and found an increased bone loss in corticosteroid treated RA patients that was more likely to be attributable to drug therapy than to disease activity.20 Although in our study there was no weight gain in the patients treated with nandrolone decanoate, there was a marked increase in total body nitrogen and potassium. The mean gain in nitrogen was of the order of 100 g, which would correspond with an increase of approximately 3 kg protein. Since there was no overall weight gain in nandrolone decanoate treated patients, this would suggest that the effect of the steroid is to alter the balance of body composition, increasing the proportion of fat free tissue.
The main side effects were hoarseness and change in voice. This worried the patients more than breast enlargement or the growth of facial hair. Although rheumatoid arthritis can cause involvement of the cricoarytenoid joint, this was not seen in the control group, and we think this more likely to be a direct result of therapy. In view of the risk of laryngeal neoplasm in this age group most patients complaining of hoarseness were referred for specialist ear, nose, and throat examination to exclude neoplasia.
No obvious cause for the deepening of the voice was found as a result of this specialist referral.
Although 19-nortestosterone modifies the immune system in systemic lupus erythematosus,2' and a related anabolic steroid, stanozolol, has been claimed to be successful in rheumatoid arthritis because of its fibrinolytic enhancing properties,22 we found no evidence that nandrolone decanoate has any disease modifying action in this study. 
